AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26
AstraZeneca Pharma India Ltd 路 Others (Uncategorized) 路 02 Sept 2026, 11:45 pm
AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26 On 2nd Sep'26, AstraZeneca Pharma India disclosed receiving an ESG rating of 64 from Crisil ESG Ratings for FY26. The assessment was conducted independently based solely on publicly available information. Management clarified that the company did not formally engage Crisil for this evaluation, emphasizing the unsolicited nature of the ESG rating assignment.
Original exchange filing (PDF)
More announcements from AstraZeneca Pharma India Ltd
- Please find the enclosed document of the Company as per the captioned subject. This is being resubmitted as the weblink was not correctly re-directing to the relevant web page in the earlier .... 路 17 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 17 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 07 Nov 2026
- AstraZeneca Pharma India Limited has informed the Exchange about General Updates 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 05 Nov 2026
- AstraZeneca Pharma India Limited has informed the Exchange about Appointment/ Change in designation of Senior Management Personnel 路 05 Nov 2026
